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High-energy ion beams are successfully used in cancer therapy and precisely deliver high doses of 
ionizing radiation to small deep-seated target volumes. A similar noninvasive treatment modality for 
cardiac arrhythmias was tested here. This study used high-energy carbon ions for ablation of cardiac 
tissue in pigs. Doses of 25, 40, and 55 Gy were applied in forced-breath-hold to the atrioventricular 
junction, left atrial pulmonary vein junction, and freewall left ventricle of intact animals. Procedural 
success was tracked by (1.) in-beam positron-emission tomography (PET) imaging; (2.) intracardiac 
voltage mapping with visible lesion on ultrasound; (3.) lesion outcomes in pathohistolgy. High doses 
(40–55 Gy) caused slowing and interruption of cardiac impulse propagation. Target fibrosis was the main 
mediator of the ablation effect. In irradiated tissue, apoptosis was present after 3, but not 6 months. 
Our study shows feasibility to use high-energy ion beams for creation of cardiac lesions that chronically 
interrupt cardiac conduction.
Disturbances of the heart rhythm, cardiac arrhythmias, are a major source for morbidity and mortality world-
wide. Arrhythmias occurring from the ventricles may lead to sudden cardiac death that is estimated to account for 
about 300,000 deaths in the United States per year1. Atrial fibrillation is an extremely common cardiac arrhyth-
mia2. The prevalence of atrial fibrillation is on significant rise as populations are ageing, placing individuals at 
increased risk for stroke, comorbidities and mortality3.
Catheter ablation, which commonly uses radiofrequency energy or cryothermal technology, has also evolved 
into a powerful treatment option for atrial fibrillation2 and ventricular tachycardia4. Yet, success rates of catheter 
ablation in these diseases are still limited. This is because the source often cannot be eliminated applying these 
presently used energy sources to endo- and epicardial surfaces of the heart5. Furthermore, catheter ablation is 
linked to several complications, including interventional risks such as silent embolic events6,7, vessel or cardiac 
wall perforation2, and atrial-esophageal fistula formation8.
These pitfalls could be overcome by noninvasive use of charged particle beams. In fact, accelerated protons 
and heavier ions (generally carbon ions) deliver most of their energy in the distal region of their path in the tissues 
(Bragg peak)9. Beam penetration depth is controlled by the initial particle energy in the accelerator. Pencil-beam 
scanning by magnetic deflection can deliver the radiation dose conformal to arbitrarily shaped targets10. Favorable 
physical and biological characteristics of charged particles compared to X-rays justify their use in cancer therapy, 
where they are considered a cutting-edge technology9. Irradiation with carbon ions can be monitored by Positron 
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(β +) Emission Tomography (PET) as nuclear fragments of target and projectile yield β +-emitters with half-lives 
of up to about 20 min11.
We have recently provided initial data to ablate cardiac arrhythmias with ion beams in isolated Langendorff- 
perfused beating heart preparations12–14. Our working hypothesis is that high-energy charged particles can be 
used to create chronic lesions that locally interrupt cardiac conduction and therefore enable treatment of heart 
rhythm disorders completely noninvasively while sparing surrounding tissues.
In this first in situ heart feasibility study, we demonstrate ablation with chronic interruption of impulse prop-
agation of several cardiac locations by using charged particle beams in a sham-controlled, large animal model 
without any required procedural access to the body.
Results
Study Design and Overview. Seventeen animals were randomized to irradiation of the atrioventricular 
junction (AVJ, n = 8), right superior pulmonary vein (RSPV) left atrial (LA) junction (n = 3), freewall left ven-
tricle (LV, n = 3), and compared to sham-procedures (n = 3). Target contours for the respective ablation location 
were placed at the AVJ, LV freewall, and LA-RSPV junction (cf. methods). Baseline characteristics of the animals 
and relevant contouring and targeting parameters are depicted in Table 1. The mean baseline left ventricular ejec-
tion fraction was 73 ± 4%. The mean duration of follow-up was 20.3 weeks. All animals of all assigned dose and 
target groups stayed in sinus rhythm during irradiation.
Atrioventricular Junction Ablation Group. Carbon Ion Beam Treatment Planning and In-Beam PET 
for Monitoring of Dose Deposition. An exemplary planned 4D-dose deposition including beam rescanning 
(cf. methods) for ablation of the contoured AVJ lesion with 55 Gy is shown in Fig. 1a. To ensure delivery of > 95% 
of the prescribed dose to the target, isotropic and anisotropic margins were added which also extended into the 
blood (target volumes see Table 1). Online PET-imaging during irradiation with 55 Gy showed strong β +-activity 
in the atrioventricular (AV) septum (Fig. 1b) and a lower signal along the beam’s entry channel. Deposition of 
40 and 25 Gy resulted in a lower but evaluable PET response. Radioactive decay and biological washout led to a 
relatively fast β +-signal reduction over a time-course of six minutes (Fig. 1c).
Surface ECG and Decremental Pacing Outcomes after Carbon Ion Irradiation. An overview of the electrophys-
iological effects of irradiation is given in Fig. 1d,e. In two out of six animals, both irradiation with 55 and 40 Gy 
led to complete AV block with presence of a junctional escape rhythm (Fig. 1d), which developed up to seventeen 
weeks after irradiation (#1, 4; Table 2). One other animal of the 55 Gy dose group did not show significant change 
in AV conduction at termination of follow-up (#2; Table 2). In the animal that developed complete AV block 
following 40 Gy (#4), block was not persistent until the end of follow-up at six months. However, an increased 
Wenckebach-point in relation to the animal’s own baseline (#4, baseline: 260 ms versus post-irradiation: 570 ms, 
Table 2) was present. Over the course of six months of follow-up, no electrophysiological effect appeared in the 













junction (n = 3)
Freewall 
LV (n = 3)
General Metrics Male sex, n (%) 13 (76) 3 (100) 2 (100) 1 (33) 3 (100) 2 (66) 2 (33)
Mean weight at imaging, kg 33.8 ± 3.4 32.5 ± 4.6 35.1 ± 3.1 35.5 ± 1.2 31.6 ± 1.7 36.5 ± 2.6 33.6 ± 2.9
Mean weight at irradiation, kg 34.2 ± 3.2 n.a. 30.2 36.4 ± 1.7 32.0 ± 1.7 35.0 ± 3.0 34.1 ± 3.9
Mean weight gain at 6 months, kg 39.8 ± 14.0 36¥ 54.3 ± 8 32.8 ¥ 50.3 ± 1.0 35.0 ± 2.1 47¥
Mean duration of follow-up, weeks 20.3 ± 5.7 18.7 ± 5.6 24.4 ± 0.1 17.3 ± 5.3 20.3 ± 5.6 24.5 ± 0.1 16.6 ± 5.6
Mean time from CT to Irradiation, days 10.9 ± 3.4 n.a. 13.5 ± 1.5 16.0 ± 1.4 14.0 ± 2.5 8 ± 0 9.3 ± 0.5
Cardiac Function Baseline LVEF (%) 73 ± 4 70 ± 2 77 ± 6 72 ± 4 78 ± 1 74 ± 1 73 ± 5
LVEF (%) at 6 months 76 ± 6 73 ± 8 75 ± 4 79¥ 79 ± 1 72 ± 2 78 ± 7
Baseline E/A wave ratio 0.91 ± 0.5 0.66 ± 0.02 0.54 ± 0.01 1.0 ± 0.5 0.7 ± 0.2 1.1 ± 0.2 1.3 ± 0.8
E/A wave ratio at 6 months 0.8 ± 0.2 0.74 ± 0.1 1.2 ± 0.1 0.6¥ 0.6 ± 0.01 0.6 ± 0.04 1.0 ± 0.3
Irradiation Parameters Mean delineated target volume (cc) n.a. n.a. 0.5 0.5 0.5 0.9 (0.8–1.1)¶ 2.3 ± 0.3
Mean target volume + margins (cc) n.a. n.a. 1.8 ± 0.1 1.8 ± 0.1 1.8 ± 0.1 14.9 ± 1.8 n.a.
Mean planning target volume (PTV, cc) n.a. n.a. 3.7 ± 0.3 3.4 ± 0.5 3.9 ± 1.0 23.2 ± 1.7 8.9 ± 1.8
Iso-energy slices, n (IES) n.a. n.a. 11.5 ± 1.5 9 ± 1.4 8.3 ± 0.5 20 ± 1 14
Beam energies, MeV n.a. n.a. 172–211 175–208 183–212 129–233 112–186
Mean treatment time (min) n.a. n.a. 15.7 7.3 10.8 23.4 ± 8.1 23.9 ± 8.6
Table 1.  Study population general metrics, results for global cardiac function and treatment planning 
parameters for all dose groups and targets. The mean planning target volume corresponds to the irradiated 
volume. AVJ = atrioventricular junction ablation; RSPV-LA junction = right superior pulmonary vein left 
atrial junction; LVEF = Left Ventricular Ejection Fraction; MeV = Megaelectronvolt; min = minutes; n.a. = not 
applicable; ¥ = Data only available for one animal. Data are depicted as mean ± standard deviation. ¶Median 
(range).
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Electroanatomical Mapping and Correlation to Macroscopic Lesion Outcome after Irradiation. To describe extent 
of the lesion that led to AV block, electroanatomical voltage mapping was conducted after twenty-four weeks 
of follow-up. In the animal that developed AV block following 55 Gy, voltage mapping revealed a lesion area of 
2.7 cm2 versus an area of 1.4 cm2 for the 40 Gy animal (Fig. 1e), concordant with macroscopically endocardial 
lesion dimensions in two planes (#1, 4; Table 2). Compared to sham-procedure animals, 55 and 40 Gy in these 
two animals reduced the mean bipolar voltage amplitude of all AVJ target location tag-points by 2.4 mV (#1; 
p < 0.0001, [n = 207]) and 2.0 mV (#4; p < 0.0001, [n = 246]), respectively. In the animal of the 55 Gy group with-
out apparent effect, the lesion was misplaced into the posterior left ventricular outflow tract.
Left Atrial Pulmonary Vein Junction Ablation Group. Treatment Planning and In-Beam PET for 
Monitoring of Dose Deposition. An exemplary coronal plane of a treatment plan for irradiation of the RSPV-LA 
junction is depicted in Fig. 2a. Despite the contoured lesion being located on the RSPV-LA junction, high-dose 
isodose lines extended into the RSPV muscular sleeve (Fig. 2a). During irradiation, PET showed only weak β 
+-activity (Fig. S1), likely due to the blood included in the target volume, that is quickly washed out.
Multielectrode Catheter Mapping after Carbon Ion Irradiation. Figure 2b displays a representative image of 
the circular multielectrode catheter positioned at the RSPV’s ostium. In one of the three studied animals (#12; 
Figure 1. Application of Carbon Ions for Atrioventricular Junction Ablation. (a) Coronal view of a treatment 
plan for irradiation of the atrioventricular junction. Dose depicted as color-wash, the target contour is shown 
in black, the enlarged target contour in white. 100% corresponds to the prescribed dose of 55 Gy. (b) Image of 
positron emission tomography after 55 Gy of carbon, projected over the coronal plane of a contrast-enhanced 
CT scan; the target contour is shown in black. (c) Decay of the detected ß+-signal over the course of six minutes. 
(d) Surface ECG (25 mm/sec) before irradiation and 17 weeks after irradiation. (e) Right anterior oblique (RAO) 
projection of right atrial electroanatomical voltage maps obtained via an intracardiac catheter with point-by-point 
sampling after ablation. Voltage legend is shown next to the image; local voltage > 1.0 mV depicted in magenta. 
Voltage < 0.5 mV depicted in red. Other colors mark voltages in-between. (f) Right lateral views of lesion outcomes 
at the tricuspid annulus; dashed lines mark the respective lesion location. AoR = Aortic root; CS = Ostium of 
coronary sinus; FO = Fossa ovalis; LAA = Left atrial appendage; LV = Left ventricle; PA = Pulmonary artery; 
RA = Right atrium; RV = Right ventricle; SL = Septal leaflet of the tricuspid valve.
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Table 2), irradiation with 40 Gy led to almost complete disappearance of local antral atrial electrograms in the 
contoured target area.
Electroanatomical Mapping after Carbon Ion Irradiation. A voltage map of the LA and RSPV before irradiation 
is shown in Fig. 2c. In this animal (#12), voltage mapping after irradiation revealed a large change in local voltage 
tag points of the atrial myocardium close to the RSPV ostium (mean ∆ : − 1.7 mV; p < 0.0001, [n = 518]). A small 
posterior-inferior gap at the carina to the inferior PV was present (Fig. 2d). Extent of the LA ablation lesion over 
the roof and anterior mitral isthmus led to change in the myocardial activation sequence with late activation 
of the LA in this animal. In the other two animals, there was a statistically significant decrease in voltage at the 
RSPV-LA junction compared to baseline present (#13, 14; Table 2), however, this was notably smaller.
Macroscopic Lesion Outcome at Termination of Follow-up. The macroscopic lesion outcome at the RSPV-LA 
junction six months after irradiation is shown in Fig. 2e (#12). The main portion of the ablation lesion was located 
in the intended area. Nevertheless, the ablation lesion extended into myocardium of the PV muscle sleeve, left 
atrial roof, and LAA, reflecting areas included into the relatively large beam deposition margin (white contour 
Fig. 2a), added to the target contour (cf. methods). In the two other cases (#13, 14; Table 2), there was no macro-
scopically visible lesion at the RSPV-LA junction present.
Outcomes in Ventricular Tissue–Freewall Left Ventricle Group. Carbon Ion Beam Treatment 
Planning and In-Beam PET for Monitoring of Dose Deposition. Target contours were located at the LV free-
wall; a treatment plan, depicting transverse and coronal planes, with two lateral beam entry fields is shown in 
Fig. 3a. Table 1 shows the mean target volume including margins to compensate for contractile cardiac motion. 
Irradiation of the LV freewall induced strong β +-activities captured in PET scanning in all animals (Fig. 3b) with 
pronounced washout due to myocardial perfusion.
Electroanatomical Mapping and Intracardiac Echocardiography for in-vivo Lesion Characterization. All three 
irradiated animals showed some beam effects in the LV target location. Table 2 (#15–17) displays outcomes in 
LV tissue after thirteen and twenty-five weeks of follow-up. In two cases, examined after thirteen weeks (#15, 16), 
Animal 
#
AV junction ablation 
Dose (Gy)
Mapping Outcome (cm2)–tag 
points with Voltage ≤ 0.3 mV
Macroscopic Lesion 




Follow-up (ms) Follow-up (weeks)
1 55¥ 2.9 2.5 Yes Yes n.a. 3° AVB 24.3
2 55 0 1.7¶ Yes¶ ¶ 10 24.2
3 55 † 0 † † † 12.4
4 40¥ 1.3 1.0 Yes Yes 310 24.3
5 40 † 0 † † † 11.6
6 40 † 0 † † † 16.0
7 25 0 0 No Yes 10 24.4
8 25 0 0.6 No Yes 50 24.3
9 Sham-group 0 0 No No 10 14.7
10 Sham-group 0 0 No No 10 14.7
11 Sham-group 0 0 No No 10 26.7
RSPV-LA junction 
Dose (Gy)
∆ Voltage (mV) Endocardial 





∆ Wenckebach end 
Follow-up (ms) Follow-up (weeks)
12 40 − 1.7*** †† Yes Yes Yes − 5 24.4
13 40 − 0.8* ¥¥ Yes No Yes 10 24.4
14 30 − 0.6* ¶¶ Yes No Yes 5 24.6
LV freewall Dose (Gy) ∆ Mean LV-Target Endocardial Voltage (mV)
Abnormal or Double 
Potentials Endo-/
Epicardial (#tags)
Macroscopic Lesion Lesion in Histology
Hyperechoic on 
TTE/ICE Follow-up (weeks)
15 40 − 0.5 ‡‡ − /10 Yes Yes Yes 12.6
16 40 − 0.6 ††† − /− Yes Yes Yes 12.6
17 40 − 3.4 *** ¥¥¥ 19/- Yes Yes Yes 24.6
Table 2.  Overview of the outcomes for all irradiated animals and the sham group. Upper row: anmals 
irradiated at the atrioventricular junction. Middle row: outcome for animals irradiated at the left atrial right 
superior pulmonary vein junction. Lower row: outcome for animals irradiated at the left ventricular freewall. 
n.a. 3° AVB = not applicable due to complete atrioventricular block. TTE = transthoracic echocardiography; 
ICE = intracardiac echocardiography; † = Deceased from device-related infection; ¥ = Complete AV block 
seventeen weeks after irradiation on surface ECG. ¶Lesion misplaced into the posterior left ventricular outflow 
tract. ∆Wenckebach describes the difference in the Wenckebach-block cycle length occurrence for the baseline 
and follow-up study. Two-sided t-test for comparison of mean voltage at the target position at baseline versus 
the mean at follow-up date. *p < 0.05; ***p < 0.0001. The following numbers state n of endocardial tag points 
included into the statistical test. ††n = 518; ¥¥ n = 529; ¶¶n = 315; ‡‡n = 408; †††n = 337; ¥¥¥n = 391.
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intracardiac echocardiography displayed a circumscribed area of hyperechoic myocardium at the LV freewall 
(Fig. 3c). Here, endocardial mapping revealed no statistically significant decrease in mean LV target voltage com-
pared to baseline (#15, 16; Table 2). Epicardial mapping, however, showed clustering of fragmented potentials 
within the target location in one of these animals (#15; Table 2). In the animal from this group followed until 
twenty-five weeks after irradiation (#17), lesion appearance on intracardiac echocardiography was similar com-
pared to thirteen weeks and endocardial mapping revealed decreased voltage within the target location (Fig. 3d) 
compared to baseline (mean baseline: 4.0 ± 2.3 versus post-irradiation: 0.6 ± 0.3; p < 0.0001, [n = 391]).
Macroscopic Lesion Outcome. Macroscopic epi- and endocardial lesion outcome is depicted in Fig. 3e,f. There 
was notable mid-myocardial as well as epicardial scar.
Lesion Histology (H&E, Mallory Trichrome) and Markers of Apoptosis Lesion Morphology. Compared to 
sham-animals, strong target fibrosis, cardiomyocyte disarray, and hemorrhage (Fig. 4b) was present in all animals 
with present blockage and macroscopically induced lesions (Table 2). Three months after irradiation, ablation 
lesions were marked by a higher degree of hemorrhage, inflammation, and early fibrosis than lesions six months 
after irradiation (Fig. 4b,c).
Dose Dependency. A comparison for the three different doses applied to the AVJ, namely 25, 40, and 55 Gy, 
is shown in Fig. 4d–f. Twenty-five Gy lead to minor fibrotic changes but, nevertheless, clearly led to manifold 
changes in the target tissue (cardiomyocyte disarray, apoptosis) while both 40 and 55 Gy in successful cases led to 
a strong fibrotic response as described above.
Tissue Apoptosis. Cleaved caspase-3 was only present in irradiated tissue after three months of follow-up, 
whereas lesions were negative for cleaved caspase-3 after six months of follow-up (Fig. 4g,h).
Figure 2. Impact of Carbon Ions on the Right Superior Pulmonary Vein Left Atrial Junction. (a) Coronal 
view of a treatment plan for irradiation of the right superior pulmonary vein (RSPV) left atrial (LA) junction. 
Details as described for Fig. 1a. (b) Right anterior oblique (RAO) view of RSPV venography and RAO of 
circumferential mapping catheter in the RSPV. Dashed red lines mark projection of RSPV. (c) Right-lateral 
projection of an endocardial electroanatomical voltage map from the left atrium (LA) and RSPV before 
irradiation. (d) Right-lateral projection of an electroanatomical voltage map of the LA and RSPV six months 
after irradiation with 40 Gy carbon ions. Voltage as in legend indicated; voltages > 0.7 mV are depicted in 
magenta and voltage < 0.2 mV in red. Other colors mark voltages in-between. (e) Macroscopic lesion outcome 
at the RSPV-LA junction. The RSPV is opened at its ostium at 12o’clock. Appreciate the macroscopically evident 
lesion with local hemorrhage and fibrosis. CS = multielectrode catheter in the coronary sinus. Circ. = the 
circumferential mapping catheter. Turquois dots = double potential. White dots = fragmented signals/area of 
slow conduction. FO = Transseptal puncture side in the fossa ovalis; LAA = left atrial appendage; MVA = Mitral 
valve annulus; RSPV = right superior pulmonary vein.
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Irradiation Toxicity during Follow-up. No damage was observed in the tissues of the esophagus, tra-
chea, or phrenic nerves. Coronary arteries did not show a reaction during six months of follow-up. There was 
no statistical significant change in left ventricular ejection fraction between irradiated animals of all groups and 
sham-animals (mean ∆ irradiation group: 2.4 ± 8.3 versus mean ∆ sham-group: 3.3 ± 6.6; p = 0.81) or between 
sham-animals and LV freewall irradiation group present (Table 1). There was also no skin reaction in the beam’s 
entry channel noted in any animal.
Discussion
This feasibility study indicates that: (i.) Heavy ion beams delivered by the raster scanning technique can be suc-
cessfully used for ablation of myocardium with chronic interruption of impulse propagation. (ii.) In-beam PET 
is an accurate means for online verification of ion beam range and dose-deposition of these small, moving, and 
highly perfused cardiac targets. (iii.) Target doses of 40–55 Gy induce complete blockage of impulse propagation; 
such blockage is to be expected between thirteen to seventeen weeks after irradiation. (iv.) Ultrasound imaging 
can be used to depict created ablation lesions. (v.) Target fibrosis is the main mediator of interruption of cardiac 
impulse propagation, while multiple non-destructive structural and subcellular changes present at lower doses 
also affect arrhythmogenesis15,16.
Despite application of charged particles in non-cancer diseases being completely novel17, carbon ion beams 
to date have been applied as cutting-edge technology for treatment of malignant tumors in more than 15,000 
patients worldwide18,19. The physical properties of charged particle beams–inverted dose-profile with major 
energy release at a specific tissue depth at the end of the particle range (Bragg peak)–enable irradiation of deep 
seated target volumes with significant sparing of surrounding structures when compared to state-of-the-art X-ray 
treatments20. In case of catheter-free arrhythmia ablation, this translates into decrease in dose-exposure of myo-
cardium as well as mediastinal structures21. In addition to irradiation of very large myocardial volumes, studies 
using radiation therapy with photon beams for catheter-free isolation of the RSPV have created accidental heart 
block and fistulas of mediastinal organs in the porcine model22.
In this study, it took between thirteen to seventeen weeks for the electrophysiological endpoint to occur. 
There was no difference in that time-course between animals irradiated with 40 Gy and animals irradiated with 
55 Gy; the time-course to occurrence of AV conduction block was longer than previously described using X-ray 
Figure 3. Outcomes after Left Ventricular (LV) Freewall Irradiation. (a) Transverse and coronal plane of a 
treatment plan with two lateral carbon beams (40 Gy). Details as described for Fig. 1a. (b) Anteroposterior view 
of by-product β +-activity during irradiation via PET, superimposed on the coronal plane of a contrast-enhanced 
CT scan. Black contour = target contour, β +-activity shown as color-wash. (c) Intracardiac ultrasound image of 
the LV freewall after irradiation, hyperechoic lesion area marked by dotted lines. (d) Left anterior oblique view 
of an endocardial voltage map of the LV 6 months after irradiation. As indicated in the legend, local voltage 
> 1.0 mV is depicted in magenta. Voltage < 0.5 mV in red. Other colors mark voltages in-between. White 
dots = fragmented potentials. (e) Macroscopic LV epicardial lesion outcome six months after irradiation with 
the dashed line marking the contoured target zone. (f) Endocardial lesion outcome six months after irradiation. 
Ao = Descending aorta; F = Freewall; LAA = Left atrial appendage; LAD = Left anterior descending coronary 
artery; LIPV = Left inferior pulmonary vein; LVOT = Left ventricular outflow tract behind the mitral valve 
leaflet; LL = Left lung; IVC = Inferior vena cava; LV = Left ventricle; LV-A = Left ventricular apex; RIPV = Right 
inferior pulmonary vein; RL = Right lung; RV = Right ventricle; S = Septal site.
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beams23,24. However, these data derive from a non-arrhythmic animal model and are based on conduction block 
only. Antiarrhythmic effects of ion beams in cardiac tissue may be multifactorial and therefore the time-course of 
true antiarrhythmic effects remains unclear. When using charged particles, the irradiated tissue volume is nota-
bly smaller and the conformity to the target volume is better than with photons, providing biophysical rationale 
for different cellular responses. Although our group has shown in isolated beating hearts that an acute electro-
physiological effect may be seen with even higher dosing12, the present study does not show acute beam effects 
on cardiac conduction, but does show chronic effects within the applied dose range. Outcomes in this study 
were not concordant within each dose and target group. The reason for the relatively low success rate of 33% in 
AV and RSPV-LA junction ablation is likely to be multifactorial; three animals in the AVJ ablation group died 
of device-related infection and thus effects in these animals could not be evaluated in a similar fashion as in 
animals from the other groups. In one animal the lesion was misplaced by 5 mm in beam direction. This could 
have, among other factors, have been caused by a change in cardiac volume status, leading to a miscalculated 
position of the Bragg Peak. Range uncertainty especially for moving targets is a major issue in particle therapy. 
State-of-the-art imaging and matching capabilities such as cone beam CT are becoming clinically available for 
heavy ion therapy and would have facilitated positioning and matching of the treatment planning CT25, making 
placement of intracardiac markers unnecessary and increasing procedural efficacy. Technical capabilities were 
also restricted to a four degrees-of-freedom treatment table, instead of six degrees-of-freedom-robotic position-
ing table that is available at ion beam centers using the latest technology. Lastly, motion compensation for scanned 
particles is challenging26 and even though considerable care was taken to suppress the effects of cardiac contrac-
tion on the dose distribution (cf. methods), we cannot fully exclude residual dosing errors.
In-beam PET-imaging successfully verified ion beam range and irradiation of the respective target location. 
However, in this applied setup no subsequent corrections to the beam range or position were possible. In a single 
Figure 4. Mallory Trichrome Staining of Ablation Lesions, and Apoptosis Outcomes. (a) Sham-control  
(b) Target tissue three month after 40 Gy carbon ion irradiation with marked hemorrhage, inflammation, and 
early stage fibrosis, (c) Target tissue six months after carbon ion irradiation, showing later stage fibrosis.  
(d–f) Comparison of myocardial lesion outcomes for 25, 40, and 55 Gy of carbon ions six months after 
irradiation for the atrioventricular junction ablation group. (g) Western blot for cleaved caspase-3 a marker for 
apoptosis; signals for cleaved caspase-3 were positive in myocardium three months after irradiation, whereas 
no signals were observed six months after irradiation (h). Bz = borderzone; ep = Epicardium; IRR = Irradiated 
tissue; LV = Left ventricle; PC: positive control HaCaT (Lysats of HaCaT cells five days after irradiation with 
10 Gy of X-ray), I = infield; Out = Outfield; RV = Right ventricle.
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fraction treatment, PET imaging right after application of a relatively smaller amount of dose could be a solution 
to make early adjustments to ion beam position and/or ion range possible27. Strong washout in these highly per-
fused target volumes was observed, underlining favorable properties of online in-beam PET for this application. 
However, combination of PET with CT or MRI as it is done offline, immediately following the treatment of dif-
ferent tumors28 provides real-time high-resolution anatomy, but at the expense of increased washout and loss of 
decays with a too short half-life.
Apoptotic markers were found positive after three months, but negative after six months. Activation of the 
apoptotic cascade, particularly of endothelial cells, is a known response to ionizing radiation in tumorous tissue29. 
In the heart, ionizing radiation lesions have also been found to start with endothelial vascular damage, ultimately 
leading to myocardial fibrosis30. To our knowledge, there is no previous data on the role and the time-course of 
activation of the apoptotic cascade as response to ionizing radiation of the in situ heart. However, the decisive role 
of apoptosis in acute myocardial infarction31 and subsequent scar remodeling is quite well established32. Dose vol-
ume relationship for cardiac targets and dependence on ablated anatomical location remains unclear. Observed 
differences between endo- and epicardial fibrosis could reflect biological underpinnings such as different vascular 
density, but could also purely be related to physical targeting issues.
Arrhythmia ablation without physically accessing the body has been tried with other less focused energy 
sources23,33 and has tremendous clinical implications. It would eliminate the side effects and the risks of introduc-
ing and ablating with catheters in the central circulation, including the formation of blood clots, embolization, 
and perforation. Ablation for ventricular arrhythmias often fails because of limited accessibility of the arrhythmia 
substrate in the ventricles using standard techniques34,35. Ionizing irradiation does have long-term side effects 
that need to be carefully evaluated in further studies with longer follow-up and risk modeling. Toxicity data for 
high-dose irradiation of small cardiac volumes is scarce. This study shows acute safety when careful treatment 
planning is conducted, nevertheless, evaluation of long-term safety requires careful future studies. Theoretically, 
the physical properties of ion beams will allow localized, volume-conformal irradiation of arrhythmogenic 
sources at any given myocardial depth. This is not limited to carbon ions, but should also be valid for lighter 
ions with similar focusing capabilities that can even be accelerated using cyclotrons. Integrating particle beam 
technologies with cardiac MRI, CT, and body surface arrhythmia mapping36 would equip us with the necessary 
technology to achieve focused, completely noninvasive arrhythmia ablation. High-energy particle beams have 
potential as a new and precise means for external arrhythmia elimination without any required procedural access 
to the body and without intrinsic restriction of tissue penetration for this energy-source.
Methods
All animal procedures and irradiation were approved by the regional board of the state of Baden-Württemberg, 
Karlsruhe, Germany (approval number G-7/14) as well as the committees of the Helmholtz Centre for Heavy Ion 
Research (GSI), Darmstadt, Germany. All animal procedures were carried out in accordance with the ‘German 
Law for Animal Research’ (Tierschutzgesetz) and with the NIH Guide for the Care and Use of Laboratory Animals 
as well as the guidelines established by the Mayo Foundation animal care and use committee.
Study Design and Randomization to Target and Dose Groups. Seventeen pigs (sus scrofa domestica) 
of either sex (weight of 30–35 kg, age ~10 weeks) were randomized to irradiation of one of three targets or to a 
sham-irradiated control group (n = 3). Eight animals were assigned to irradiation of the AVJ. Here, in addition, 
randomization to dose (25 [n = 2], 40 [n = 3], and 55 Gy [n = 3]) was performed. Three pigs were randomized 
to irradiation of the RSPV-LA junction (40 Gy) and three animals to LV freewall irradiation (40 Gy). All animals 
received a baseline study, assessing pertinent cardiac parameters for later detailed evaluation of beam effects on 
myocardium. None of the information from this study was integrated and used for the actual guidance of beam 
delivery, which only relied on the CT image and the here extracted cardiac motion data. Three to six months after 
single fraction irradiation, animals underwent follow-up evaluation and were euthanized, tissues were harvested, 
and additional experiments were conducted as described below. All endpoints were prospectively selected.
In ion beam therapy for cancer, models predict the relative biological effectiveness (RBE) with the goal of 
delivering a biologically effective dose of carbon ions in Gy (RBE) with the same effect as a physical dose of pho-
tons in Gy. Due to the highly localized energy deposition of carbon ions leading to complex DNA damage, RBE 
values for carbon for typical dose ranges of 2–4 Gy/fraction are in the order of 337. The RBE is dose-dependent; 
for very high single fraction doses used here, the RBE is likely considerably closer to 138. RBE-models were estab-
lished for cancerous cell killing, while the endpoint of influencing cardiac electrophysiology is completely unstud-
ied. Therefore, we decided to use physical doses for the carbon beam treatment planning.
Anesthesia and Surgical Care for Invasive Baseline and Follow-up Studies. Anesthesia was 
induced using an intramuscular injection of ketamine (100 mg/kg, Roche, Grenzach-Wyhlen, Germany), azaper-
one (2 mg/kg, Janssen Pharmaceutica, Beerse, Belgium), and midazolam (0.5 mg/kg, Roche, Grenzach-Wyhlen, 
Germany). In case of electrophysiological studies, after intubation, animals were maintained on 1–3% inhaled iso-
flurane (Baxter, Unterschleißheim, Germany) for anesthesia. ECG was monitored using four surface electrodes. 
Invasive arterial blood pressure, digital pulse oximetry, and end-tidal CO2 were constantly monitored. Analgesia 
after the procedure was achieved using morphine s.c. (1 mg/kg, Pfizer, NY, USA).
Baseline Electrophysiological Study. Twelve-lead ECGs were obtained. Transthoracic echocardiography 
(Philips Healthcare Sonos 5500, Hamburg, Germany) was performed in a supine position. Skin was prepped 
using Braunol® (B. Braun, Melsungen, Germany). For vascular access, cut-downs with vessel preparation for 
placement of introducer sheaths in the left/right external jugular vein and the right/left femoral arteries and veins 
were performed. A 7Fr decapolar catheter was advanced into the coronary sinus (CS) from the external jugular 
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vein for electrogram recordings. All catheterization was performed under fluoroscopic guidance (Siremobil 
Combact L, Siemens Healthcare, Forchheim, Germany). For ultrasound imaging during the procedure, an intra-
cardiac echocardiography (ICE [Acuson, Cypress, Mountain View, CA, USA]) with a 10Fr 5.5–10 MHz probe was 
used. For LA and LV access, a transseptal puncture was performed under ICE guidance using a BRKTM needle (St. 
Jude Medical, St. Paul, MN, USA) through a SL1 sheath. Electroanatomical mapping was performed using a map-
ping system (Carto XP, Biosense Webster, Inc., Diamond Bar, CA, USA). Angiograms of right and left coronary 
arteries were performed using an AL-1 catheter (Cordis, Johnson and Johnson®, USA). One intracardiac marker 
was implanted (right atrial appendage) with an endovascular technique, serving as fiducial during biplane X-ray 
positioning for irradiation (Quick Clip 2, 8 mm × 2 mm, Olympus, Shinjuku, Japan).
Atrioventricular Junction Ablation and Sham-Group. Electroanatomical mapping with creation of 
three-dimensional, voltage, and activation maps was performed. A Navistar mapping catheter with a 3.5 mm 
distal tip electrode, 2.0 mm ring electrode, and 1 mm interelectrode distance was used (Biosense Webster, Inc., 
Diamond Bar, CA, USA). Around 200 points were sampled (fill-threshold < 15 mm; high-density map) per cham-
ber. Intracardiac signals were sampled at 1 kHz and filtered at 30–250 Hz (Bard medical, Covington, GA, USA). 
Bipolar voltage of endocardial target tag-points before and after irradiation was compared. Atrial signals of cor-
onary sinus (CS) 1–2 were used as reference electrogram. Function of the AVJ was assessed using the work-flow 
described by Bunch et al.39. Antegrade decremental pacing was performed from the high right atrium, beginning 
at a cycle length 20 ms shorter than the sinus rate, down to 200 ms. The cycle length at which Wenckebach block 
occurred was established. AVJ ablation and sham-animals underwent dual chamber pacemaker implantation at 
the end of the baseline study. Preparation of the external jugular vein was performed. Two 7Fr active fixation pac-
ing leads were introduced through two small incisions in the vessel wall. Atrial leads were placed in the right atrial 
appendage and right ventricular leads were placed in the right ventricular apex. Leads were connected to a pace-
maker unit (Medtronic Inc., Minneapolis, MN, USA) placed in a subcutaneous pocket in the neck. Pacemakers 
were programmed in the DDI mode with a lower pacing rate of 60 bpm.
Pulmonary Vein Isolation Group. A steerable 8Fr sheath was used for LA mapping (Agilis, St. Jude Medical, 
St. Paul, MN, USA). A 7Fr decapolar circular mapping catheter (Biosense Webster, Palo Alto, CA, USA) was 
advanced into the RSPV-LA junction for recording of PV potentials. Recordings were obtained in sinus rhythm 
and during pacing. Electroanatomical mapping of the LA, RSPV-LA junction, CS, and right atrium adjacent to 
the RSPV was conducted. The atrial electrogram from CS 1–2 was used as reference. Bipolar voltage of endocar-
dial target tag-points before and after irradiation was compared.
Left Ventricular Ablation Group. LV electroanatomical mapping was performed using a retrograde transaortic 
and/or transseptal approach. The surface QRS complex was used as mapping reference. Percutaneous epicardial 
access was obtained using a 6 inch, 17 gauge Tuohy needle inserted through a small sub-xiphoidal incision under 
fluoroscopic guidance40. After guidewire access to the epicardial space was confirmed, an 8Fr introducer sheath 
was inserted over the wire and positioned in the pericardial sac. Electroanatomical mapping of the epicardial 
surface of the LV was performed. Bipolar voltage of endocardial target tag-points before and after irradiation was 
compared.
Sedation and Ventilation during Computed Tomography and Carbon Ion Irradiation. Sedation 
was induced as described above. Sedation during CT scanning and irradiation was maintained through intrave-
nous infusion of propofol (10 mg/cc; 0.25–0.30 mg/kg/min, Diprivan, Fresenius, Bad Hoburg, Germany) with-
out need for additional paralytic use for ventilator and breath-hold compliance. Oxygenation was maintained 
through intermittent-positive pressure ventilation (IPPV, Evita XL, Draeger, Lübeck, Germany).
Four-Dimensional Computed Tomography Acquisition. Sedated animals were immobilized using a 
vacuum mattress and thermoplastic mask for reproducible positioning (Fig. S3). The CT reference point (cali-
brated room laser) was marked on the mask with radio-opaque markers and tattooed on the skin. Cardiac-gated 
(4-dimensional [D]), native and contrast-enhanced CT scans (10 phases) were acquired using a 64 row Siemens 
Somatom Definition Flash scanner (Siemens Healthcare, Forchheim, Germany). Scans were acquired at 
end-expiration using a 25 sec. respirator breath-hold remotely controlled through a Labview software interface 
(National Instruments, Austin, TX, USA). For enhanced scans, 50cc contrast medium were injected (4cc/sec, 
8–10 sec. delay, Omnipaque 350 mg I/cc, GE Healthcare, USA). A field of view of 400 mm and 1 mm slice thick-
ness was reconstructed. The native 4D-CT protocol was validated against the standard planning CT protocol of 
the Heidelberg Ion Beam Therapy Center (HIT) for correct HU and resulting ion beam ranges.
Target Definition and Contouring in Computed Tomography Images. CT contouring to define 
specific structures was performed using Syngo® PRT Planning (VC11B, Siemens AG, Erlangen, Germany) and 
EclipseTM (Varian medical, Palo Alto, CA, USA) treatment planning software as described41. Briefly, a 5 mm 
sphere was contoured for AVJ ablation. RSPV-LA junction and LV freewall ablation lesions were defined by poly-
gons in the transverse CT slices. In addition, organs and structures at risk (OAR) such as the esophagus, trachea, 
aorta, and coronary arteries, were demarked on the 0% R-R phase of the 4D-CT.
Four-Dimensional Carbon Ion Beam Treatment Planning. Treatment planning was conducted using 
GSI’s treatment planning software TRiP4D42. A treatment plan for scanned charged particles consists of sets of 
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pencil beams of the same energy or range in water (iso-energy slices, IES). Pencil beams were arranged on a regu-
lar grid with 2 mm lateral distance. Along the beam axis, IES were spaced 3 mm apart in water. A so-called ripple 
filter broadened the Bragg peak to approximately 3 mm, so that homogeneous doses could be applied43. Through 
optimization, particle numbers were assigned to each pencil beam, so that the whole plan conforms with dose 
prescription to target and OARs.
To extend contours and doses across the 4D-CT phases, deformable image registration (DIR) was performed 
and yielded a voxel-to-voxel map between reference (0% R-R) and remaining motion phases (Plastimatch version 
1.15.17)44. Quality assurance of registration was conducted by visualization of the vector field, false color, check-
erboard images, propagation of contours, and the Jacobian matrix45. DIR was computed on the contrast-enhanced 
4D-CTs but applied to native images, as contrast agent falsifies ion range information46. Target volumes of AVJ 
and PVI were isotropically expanded by 5 mm to account for setup errors. For LV freewall irradiation, 2 mm + 2% 
range margin (target depth uncertainty) was added. Using DIR, volumes were propagated to each phase and 
field-specific target volumes, including target motion and motion-induced range changes were obtained for all 
4DCT phases (planning target volume = PTV)47. In scanned particle therapy, interference between the scanning 
motion of the beam and target motion leads to major dose errors (interplay)48. Delivery margins do not help 
against interplay, but repeated irradiation of each IES (rescanning) leads to averaging and a homogeneous target 
dose49. Four-dimensional treatment planning studies were conducted for all cases to ensure safe and appropriate 
delivery parameters despite contractile motion. Interplay was simulated using a detailed description of irradiation 
timing and several ECG tracings with variable heart rates42.
Using the ECG, the appropriate 4D-CT phase was determined for each pencil beam, allowing 4D-dose calcu-
lation. Total dose was accumulated in a reference phase using DIR. In these simulations, 15 slice-by-slice rescans 
were sufficient for motion compensation. Acceptable dose to the target was assumed if 95% of the contoured tar-
get received > 95% of the prescribed dose (> 90% including safety margins) in 4D simulations. For faster irradia-
tion, full rescan cycles were only applied to the dominant, high energy IES and were reduced for lower energies.
Doses to OAR were studied. Constraints for trachea, aorta, and esophagus derived from single fraction lung 
cancer radiotherapy50. For AVJ and LV irradiation, two fields were individually optimized to a homogeneous 
dose, leading to robust irradiation without gradients. For RSPV-LA junction, irradiation fields were optimized 
simultaneously permitting gradients between fields in the target to better spare the esophagus (intensity modu-
lated particle therapy IMPT). For one animal the RSPV-LA junction dose had to be reduced to 30 Gy for sufficient 
sparing of the esophagus. In simulations, a margin size of 5 mm for AVJ and RSPV-LA junction was determined 
as the minimally acceptable margin, ensuring target coverage after repositioning, without sacrificing dose con-
straints to OARs.
Quality Assurance for Charged Particle Irradiation. For quality assurance (QA), all treatment plans 
were irradiated into a water phantom prior to actual delivery. Dose was measured by pinpoint ionization cham-
bers attached to an industrial robotic arm51. Static and dynamic QA was performed, with the arm being station-
ary or moving in the motion trajectory extracted from the cardiac 4DCT. Measured dose was compared against 
corresponding (4D) calculations.
Charged Particle Irradiation. Irradiation was carried out at the GSI Helmholtz Centre for Heavy Ion 
Research, Darmstadt, Germany where a single horizontal beam line is used. Pigs were immobilized in the same 
device used for treatment planning imaging (Fig. S2). Masks and skin tattoos were aligned to the room-laser. 
Positional concordance was ensured using repeated matching of two orthogonal X-ray images to CT-derived 
digitally reconstructed radiographs followed by repositioning using the treatment table (four degrees of free-
dom). Pencil beam scanning followed the raster-scanning technique with rescanning. Beams were irradiated 
using breath-holds at expiration. The average pencil beam focus size in the isocenter was 6.5 mm (full width at 
half maximum).
In-Beam Positron Emission Tomography (PET) Imaging. For monitoring of dose deposition, detec-
tion of β +-activity resulting from fragmentation of target and projectile nuclei was performed. Scans were 
obtained during and immediately after irradiation to study washout phenomena. GSI has a dedicated two-head, 
in-beam PET camera integrated into the treatment side11,52. For imaging, detector heads (CTI PET Systems Inc., 
Knoxville, TN, USA) were positioned above and below the treatment couch. PET was conducted in expiration 
for the first delivered field to avoid superimposed activity from subsequent irradiation52. Presented PET images 
display activity produced through half of the total delivered dose. PET activity was superimposed on the recon-
structed treatment planning contrast-enhanced CT for better visualization of cardiac anatomy.
Follow-up after Irradiation. Animals were followed for up to six months after irradiation. Twelve-lead 
ECGs and device interrogations were performed after 4, 8, 13, and 24 weeks. At follow-up termination, animals 
underwent repeat electrophysiological study as described above. Animals were euthanized at the end of the last 
invasive follow-up procedure through intracardiac potassium injection.
Pathological Examination. Heart, lungs, trachea, phrenic nerves, and esophagus were removed en block 
with the pericardium intact. Pericardial fluid was drained and collected. Gross pathological findings were assessed 
and documented. Triphenyltetrazolium chloride was used to delineate the ablation lesions. Skin biopsies of the 
beam entry channel (in-field) and control samples (out-field) were obtained at baseline and during the follow-up 
procedures and processed for evaluation.
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Histological Examination. Histological analysis was conducted on all animals. Samples were fixed 
in 4% formaldehyde and processed as described53. Subsequently, samples were wax embedded and cut with a 
microtome. Cut sections (5 μ m) were stained with Hematoxylin & Eosin and Mallory Trichrome for evaluation 
using light microscopy.
Protein Extraction and Western Blotting. Protein lysation and Western blotting were conducted 
according to our protocols53,54, on all specimens. Used antibodies were anti-caspase-3, anti-tubuline (Sigma 
Aldrich), and horseradish peroxidase-conjugated secondary antibodies (GE Healthcare Life Sciences). Protein 
expression was visualized using enhanced chemiluminescence (ECL, Amersham Biosciences) and detected on 
films (ECL-Hyperfilm, Amersham Biosciences).
Statistical Analysis. Statistical analyses were performed using IBM’s SPSS software (version 23.0). Three 
animals deceased from device-related infection; follow-up data of these animals was included until the available 
date of death and all other data was included. Continuous variables are presented as mean ± standard deviation or 
in case of skewed distribution as median and range. Comparison of voltage mapping data for each animal before 
and after irradiation was performed using a two-sided t-test (Table 2) or Mann-Whitney’s U test depending upon 
distribution of variables. The mean target tag-point voltage at baseline was compared to mean target tag-point 
voltage after irradiation. A p-value < 0.05 was considered to indicate statistical significance.
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